Navigation Links
Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
Date:11/28/2007

VIENNA, Austria, November 28 /PRNewswire/ -- f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, today announced that it has raised EUR 3.0 million from Novo A/S in a Second Closing of its Series A financing round, originally co-led by Aescap Venture and Atlas Venture. After this Second Closing, the amount raised in the Series A round increases to EUR 9.0 million. In total, the Company has raised EUR 13.0 million since inception in 2006.

With more than EUR 7 billion under management in total, Novo A/S manages the assets of the Danish Novo Nordisk Foundation and is the holding company of the Novo Group. Novo A/S is recognized as a significant force in life science venture capital with operations in Copenhagen, London and San Francisco, annual investments of approximately EUR 70 million and a worldwide portfolio of 40+ life science portfolio companies.

"We are excited to welcome Novo A/S as a new shareholder in f-star", Gottfried Himmler, CEO, commented on the financing. "It is a significant boost to our long term objective of building f-star to become a major player in the next generation antibody field. With its evergreen structure and its unparalleled financial muscle, Novo A/S is the ideal shareholder for us to build a company to last."

Commenting on the transaction, Kim Dueholm, a partner in Novo A/S said: "We are very excited to join f-star as a new shareholder. f-star has managed to build a strong intellectual property position in the exciting field of novel antibody scaffolds. This strong proprietary position, the unique properties of f-star's proprietary scaffold (Fcab(TM)), the outstanding know-how and experience of the management team and the strength of f-star's investor base make f-star a perfect addition to Novo's portfolio. " Kim is responsible for the f-star investment at Novo A/S and will join f-star's Board.

Combined with existin
'/>"/>

SOURCE f-star Biotechnologische Forschungs- und Entwicklungs-GmbH
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
2. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
3. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
4. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
5. Antibody Engineering Company f-Star Appoints Geert Mudde as Chief Scientific Officer
6. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
7. Abbott Scientists Create One Molecule With Two Antibody Functions
8. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
9. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
10. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
11. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... August 31, 2014 2014 ... is a professional and in-depth research report ... basic Polyacrylamide information, including Polyacrylamide definition, classification, ... as industry overview. This research covers the ... well as global industry analysis covering macroeconomic ...
(Date:8/29/2014)... Electronic circuits are based on electrons, but one of ... photonic circuits, i.e. circuits based on light (photons) instead ... to create a stream of single photons and control ... sorts of attempts to achieve this control, but now ... creating a steady stream of photons emitted one at ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the six ... otherwise, are expressed in Canadian dollars and presented ... Second Quarter 2014 Highlights , Announced ... acuity (VA) primary endpoint for subjects enrolled in ...
(Date:8/29/2014)... August 29, 2014 A major challenge ... biotech start-up dense realm of Boston-Cambridge, is gaining visibility ... investors. James Sherley, the Director of Boston’s Adult Stem ... local and national visibility of his company an important ... , In addition to a social media marketing ...
Breaking Biology Technology:International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... May 16, 2011 Palatin Technologies, Inc. (NYSE Amex: ... dysfunction indications and PL-3994 for acute asthma and other indications, ... 2011. Recent Highlights ... Administration (FDA), Palatin submitted a revised protocol to the FDA ...
... May 13, 2011 InterMune, Inc. (Nasdaq: ... results from two Phase 3 trials demonstrating that treatment ... associated with favorable effects on lung function, 6-minute walk ... mild to moderate idiopathic pulmonary fibrosis (IPF).  IPF is ...
... Novavax, Inc. (Nasdaq: NVAX ) a clinical-stage ... of Novavax, will be presenting at the NOBLE FINANCIAL 7th ... The Hard Rock Hotel, Hollywood, FL.  A live audio-only webcast ... website at www.novavax.com under Investors/Events. ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 2Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 3Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 4Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 5Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 6Pirfenidone Phase 3 Results Published Today in The Lancet 2Pirfenidone Phase 3 Results Published Today in The Lancet 3Pirfenidone Phase 3 Results Published Today in The Lancet 4Pirfenidone Phase 3 Results Published Today in The Lancet 5Pirfenidone Phase 3 Results Published Today in The Lancet 6
(Date:8/29/2014)... researchers explored the type and number of connections in ... plays on robustness in a study published in ... found that the assortativity signature contributes to a network,s ... that varying the out-out assortativity of TFN models has ... the other three types of assortativity," said Dov A. ...
(Date:8/29/2014)... German . ... considered the oldest form of communication. Acting as messenger ... the sexual attraction between males and females. Fish rely ... reproductive behavior in males and females. Scientists at the ... in Faro, Portugal, and at the Max Planck Institute ...
(Date:8/29/2014)... In a cell,s nucleus, chromosomal DNA is tightly ... amalgam biologists call chromatin. Until about two decades ... the mere packing material around which the glamorous ... developed a greater appreciation for how DNA/histone interactions ... multiple research institutions studying the sequence of the ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Ready for mating at the right time 2Ready for mating at the right time 3'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3
... Elastin-like polypeptides (ELPs) cause plants to store GM proteins ... degradation processes and increasing the overall protein yield. Researchers ... have visualised the mechanism by which the synthetic ... Menassa worked with a team of researchers from Agriculture ...
... chemical found in blueberry leaves has shown a strong effect ... up a new avenue for treating chronic HCV infections, which ... cirrhosis and liver cancer. Among the areas of ... southern Japan, a trend that led Hiroaki Kataoka and colleagues ...
... is recording its highest-ever winter water temperatures of more than ... to a strengthening of an ocean current originating north of ... remarkable phenomenon a significant extension of the Leeuwin Current ... far north as St Helens. Remote sensing specialists at ...
Cached Biology News:Highest ever winter water temperatures recorded 2
... used to test the crossreactivity of an ... are commonly used as blocking reagents or ... 21 different protein preparations on a nitrocellulose ... species specificity, QC of purified antibodies, selection ...
... HEXALIGHT robot is based on PI's experience ... more than a decade. PI Hexapods were ... and antenna adjustments over wide ranges in ... degrees of freedom with 3 m minimum ...
... Life Sciences can provide custom microplate coating using advanced automated ... variety of plate formats. We can also accommodate virtually any ... of 0.5-320 L):, , ... 96 well microplate, 384 well ...
... full length insert sequencing service for large ... fosmids. Agencourt utilizes unique library construction ... There are several features that allow Agencourt ... rapid turnaround including our patented magnetic bead-based ...
Biology Products: